Exencial Wealth Advisors LLC Has $11.89 Million Holdings in Medtronic plc (NYSE:MDT)

Exencial Wealth Advisors LLC lessened its stake in shares of Medtronic plc (NYSE:MDT) by 15.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 148,858 shares of the medical technology company’s stock after selling 27,569 shares during the quarter. Exencial Wealth Advisors LLC’s holdings in Medtronic were worth $11,891,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Darwin Wealth Management LLC bought a new stake in Medtronic during the third quarter worth approximately $27,000. Stephens Consulting LLC lifted its stake in shares of Medtronic by 145.7% in the fourth quarter. Stephens Consulting LLC now owns 344 shares of the medical technology company’s stock worth $27,000 after buying an additional 204 shares during the last quarter. J. Stern & Co. LLP bought a new stake in shares of Medtronic during the 3rd quarter worth $30,000. Fiduciary Advisors Inc. bought a new stake in shares of Medtronic during the 4th quarter worth $36,000. Finally, Kieckhefer Group LLC acquired a new position in Medtronic in the 4th quarter valued at $40,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Trading Up 2.4 %

Shares of Medtronic stock opened at $94.20 on Tuesday. The company’s fifty day moving average price is $87.34 and its two-hundred day moving average price is $87.57. The firm has a market capitalization of $120.82 billion, a PE ratio of 28.63, a price-to-earnings-growth ratio of 2.22 and a beta of 0.84. Medtronic plc has a 52-week low of $75.96 and a 52-week high of $95.57. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.90 and a quick ratio of 1.39.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, February 18th. The medical technology company reported $1.39 earnings per share for the quarter, beating analysts’ consensus estimates of $1.36 by $0.03. The business had revenue of $8.29 billion for the quarter, compared to analysts’ expectations of $8.33 billion. Medtronic had a net margin of 12.83% and a return on equity of 14.07%. On average, analysts expect that Medtronic plc will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 10th. Investors of record on Friday, December 27th were given a dividend of $0.70 per share. The ex-dividend date was Friday, December 27th. This represents a $2.80 annualized dividend and a dividend yield of 2.97%. Medtronic’s dividend payout ratio (DPR) is presently 85.11%.

Insider Activity at Medtronic

In other Medtronic news, EVP Brett A. Wall sold 12,437 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $90.00, for a total transaction of $1,119,330.00. Following the completion of the transaction, the executive vice president now directly owns 40,979 shares in the company, valued at $3,688,110. This represents a 23.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.20% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Barclays boosted their target price on shares of Medtronic from $105.00 to $109.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 26th. Needham & Company LLC reissued a “hold” rating on shares of Medtronic in a research report on Wednesday, February 19th. UBS Group raised their target price on Medtronic from $85.00 to $95.00 and gave the company a “neutral” rating in a report on Wednesday, February 19th. Sanford C. Bernstein upped their price target on Medtronic from $96.00 to $97.00 and gave the stock an “outperform” rating in a report on Wednesday, November 20th. Finally, Wells Fargo & Company lowered their price objective on shares of Medtronic from $106.00 to $98.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Medtronic has a consensus rating of “Hold” and an average price target of $95.00.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.